Kevin Waters - 07 Mar 2023 Form 4 Insider Report for PROCEPT BioRobotics Corp (PRCT)

Role
EVP, CFO
Signature
/s/ Jonathan Stone, Attorney-in-Fact for Kevin Waters
Issuer symbol
PRCT
Transactions as of
07 Mar 2023
Net transactions value
-$1,030,009
Form type
4
Filing time
09 Mar 2023, 16:24:03 UTC
Previous filing
21 Feb 2023
Next filing
17 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRCT Common Stock Sale $243,705 -7,136 -8.2% $34.15 79,724 07 Mar 2023 Direct F1
transaction PRCT Common Stock Sale $757,547 -22,046 -28% $34.36 57,678 08 Mar 2023 Direct F2
transaction PRCT Common Stock Sale $28,757 -818 -1.4% $35.16 56,860 07 Mar 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.0000 to $34.7400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.0000 to $34.9925, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.0000 to $35.3600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.